<DOC>
	<DOCNO>NCT01281878</DOCNO>
	<brief_summary>In study investigator prospectively analyze reduction urinary oxalate excretion treatment PLP dosages 5mg/kg/day 20 mg/kg/day serum level response relationship PLP i.v . solution use orally 12 patient primary hyperoxaluria type I inherit autosomal-recessive-disorder lead increase endogenous oxalate production , urolithiasis end stage renal disease .</brief_summary>
	<brief_title>Trial Treatment Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<criteria>Documentation diagnosis PH I one follow : Liver biopsy confirmation deficient liver specific peroxisomal alanineglyoxylate aminotransferase , ( AGT mislocalization AGT peroxisomes mitochondrion ) Homozygosity compound heterozygosity know mutation causative gene ( AGXT ) PH I Male female subject 5 year 60 year age Renal function define estimate GFR &gt; 60 ml/min normalize 1.73 m2 body surface area Subjects receive pyridoxalphosphate study must willing discontinue therapy pyridoxalphosphate wash phase least 4 week always normalization serum pyridoxalphosphate level Written inform consent patient and/or legally acceptable representative Pregnant lactate woman Women childbearing potential use highly effective contraception method pearlindex &lt; 1 . Highly effective contraception method oral , transdermal , injectable , implanted contraceptive , IUD , abstinence , sterile sexual partner must agree continue use precaution pyridoxalphosphate study Subjects post liver kidney transplantation combine transplantation Chronic diarrhoea risk malabsorption Any abnormal finding physical examination laboratory evaluation , opinion investigator , indicative disease would compromise safety take pyridoxalphosphate per os absorption Subjects participate clinical trial investigational product 4 week prior trial entry , trial 4 week trial Subjects unable take trial medication Subjects unable collect 24hour urine sample follow study procedure Subjects treatment LDopa , Isoniazid , DPenicillamine ( interaction drug pyridoxalphosphate know might influence serum pyridoxalphosphate level ) Subjects known allergy substances content ( e.g . Potassium sorbet , raspberry syrup ) Subjects confined institution judicial official behalf Subjects dependency sponsor PI trial</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>primary hyperoxaluria</keyword>
	<keyword>Pyridoxal-phosphate</keyword>
</DOC>